Effect of Amiloride to Retinal Toxicity Induced by Tissue Plasminogen Activator
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: The effects of amiloride on cellular toxicity caused by tissue plasminogen activator (tPA) in mouse primary retinal cells were investigated. Methods: Primary retinal cell cultures were maintained using glial conditioned medium. Commercial tPA and L-arginine were added, and the level of cyclic guanosine monophosphate (cyclic-GMP) in the culture supernatant was assessed using an ELISA assay. We measured the cell viability of cultured retinal cells pretreated with three different concentrations of amiloride (1, 10, and 100 μm) in addition to commercial tPA or L-arginine treatment. Results: After exposing the cultured mouse retinal cells to tPA plus L-arginine or L-arginine alone, cyclic-GMP concentrations were 61.9 ± 5.1 pmole/mL and 63.1 ± 6.1 pmole/mL, respectively. However, the control group had a significantly lower concentration of cyclic-GMP (37.2 ± 3.4 pmole/mL, p < 0.01). The cyclic GMP-dissolved solution did not cause retinal cell death. In the control group and the group treated with 1 μm amiloride and tPA containing L-arginine, the cell viability was 43.7% and 44.5%, respectively. However, cell viability increased to 70.6% with 10 μm amiloride and 78.4% with 100 μm amiloride (p = 0.015). Conclusions: L-arginine increases intracellular cyclic-GMP and may give rise to retinal cells through this mechanism. In addition, amiloride in concentrations greater than 10 μm protects against L-arginine-induced retinal cell death.
Abstract
Purpose: The effects of amiloride on cellular toxicity caused by tissue plasminogen activator (tPA) in mouse primary retinal cells were investigated. Methods: Primary retinal cell cultures were maintained using glial conditioned medium. Commercial tPA and L-arginine were added, and the level of cyclic guanosine monophosphate (cyclic-GMP) in the culture supernatant was assessed using an ELISA assay. We measured the cell viability of cultured retinal cells pretreated with three different concentrations of amiloride (1, 10, and 100 μm) in addition to commercial tPA or L-arginine treatment. Results: After exposing the cultured mouse retinal cells to tPA plus L-arginine or L-arginine alone, cyclic-GMP concentrations were 61.9 ± 5.1 pmole/mL and 63.1 ± 6.1 pmole/mL, respectively. However, the control group had a significantly lower concentration of cyclic-GMP (37.2 ± 3.4 pmole/mL, p < 0.01). The cyclic GMP-dissolved solution did not cause retinal cell death. In the control group and the group treated with 1 μm amiloride and tPA containing L-arginine, the cell viability was 43.7% and 44.5%, respectively. However, cell viability increased to 70.6% with 10 μm amiloride and 78.4% with 100 μm amiloride (p = 0.015). Conclusions: L-arginine increases intracellular cyclic-GMP and may give rise to retinal cells through this mechanism. In addition, amiloride in concentrations greater than 10 μm protects against L-arginine-induced retinal cell death.
참고문헌 (18)
- Pennica D, "Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli", Nature, 301, pp.214~221 (1983)
- Collen D, "Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells", J Pharmacol Exp Ther, 231, pp.146~152 (1984)
- Hassan AS, "Management of submacular hemorrhage with intravitreous tissue plasminogen activator injection and pneumatic displacement", Ophthalmology, 106, pp.1900~1906 (1999)
- Hattenbach LO, "Intravitreous injection of tissue plasminogen activator and gas in the treatment of submacular hemorrhage under various conditions", Ophthalmology, 108, pp.1485~1492 (2001)
- Peyman GA, "Tissue plasminogen activating factor assisted removal of subretinal hemorrhage", Ophthalmic Surg, 22, pp.575~582 (1991)
- Kamei M, "Surgical removal of submacular hemorrhage using tissue plasminogen activator and perfluorocarbon liquid", Am J Ophthalmol, 121, pp.267~275 (1996)
- Lewis H, "Tissue plasminogen activator-assisted surgical excision of subfoveal choroidal neovascularization in age-related macular degeneration: a randomized, double-masked trial", Ophthalmology, 104, pp.1847~1851 (1997)
- Haupert CL, "Pars plana vitrectomy, subretinal injection of tissue plasminogen activator, and fluid-gas exchange for displacement of thick submacular hemorrhage in age-related macular degeneration", Am J Ophthalmol, 131, pp.208~215 (2001)
- Johnson MW, "Retinal toxicity of recombinant tissue plasminogen activator in the rabbit", Arch Ophthalmol, 108, pp.259~263 (1990)
- 이준행, "Retinal toxicity of commercial tissue plasminogen activator is mediated by the induction of nitric oxide in the mouse retinal primary cells", Current Eye Research, 30(4), pp.291~297, Swets & Zeitlinger
- Moncada S, "Biosynthesis and actions of nitric oxide", Semin Perinatol, 15, pp.16~19 (1991)
- Rohrer B, "Multidestructive pathways triggered in photoreceptor cell death of the rd mouse as determined through gene expression profiling", J Biol Chem, 279, pp.41903~41910 (2004)
- McLatchie LM, "The effect of pH on the block by L-cis-diltiazem and amiloride of the cyclic GMP-activated conductance of salamander rods", Proc Biol Sci, 255, pp.231~236 (1994)
- Ho AK, "Inhibitory effects of amilorides on pinealocyte adenosine 3’,5’-monophosphate and guanosine 3’,5’-monophosphate accumulation: possible involvement of postreceptor mechanisms", Endocrinology, 127, pp.460~466 (1990)
- Shimizu S, "Induction of apoptosis as well as necrosis by hypoxia and predominant prevention of apoptosis by Bcl-2 and Bcl-XL", Cancer Res, 56, pp.2161~2166 (1996)
- Koh JY, "Quantitative determination of glutamate mediated cortical neuronal injury in cell culture by lactate dehydrogenase efflux assay", J Neurosci Methods, 20, pp.83~90 (1987)
- Moncada S, "Biosynthesis of nitric oxide from L-arginine: a pathway for the regulation of cell function and communication", Biochem Pharmacol, 38, pp.1709~1715 (1989)
- Kurenny DE, "Modulation of ion channels in rod photoreceptors by nitric oxide", Neuron, 13, pp.315~324 (1994)